{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:39:46Z","timestamp":1753889986067,"version":"3.41.2"},"reference-count":40,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Introduction: Aerosolised drugs have been approved for several diseases such as cystic fibrosis and diabetes. Moreover; there are already drugs for pulmonary hypertension in aerosol form already on the market. Materials and methods: Two drugs for pulmonary hypertension (Tadalafil and Macitentan) were milled and transformed from tablets to powder. Three different jet-nebulizers with seven different residual cups were combined. Moreover, we used 3 different ultrasound nebulizers with two different release methods. Results: The drug and residual cup designs produce alone or jointly different MMAD diameters. The three large (10 mls) residual cups with the jet-nebulisers produced the smallest aerosol droplets. Both ultrasound nebulisers are capable of producing optimal size aerosol droplets \u22645 \u03bcm mmad. Conclusions: These two drugs can be easily administered as aerosol and an vivo clinical study will prove the safety for the airways.<\/jats:p>","DOI":"10.31083\/j.fbl2701019","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T08:39:39Z","timestamp":1642235979000},"source":"Crossref","is-referenced-by-count":0,"title":["Modification Tadalafil and Macitentan tablets to aerosol"],"prefix":"10.31083","volume":"27","author":[{"given":"Paul","family":"Zarogoulidis","sequence":"first","affiliation":[{"name":"Pulmonary Department, \u201cBioclinic\u201d Private Hospital, 115 24 Thessaloniki, Greece"},{"name":"3rd University General Hospital, \u201cAHEPA\u201d University Hospital, 546 21 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Petridis","sequence":"first","affiliation":[{"name":"Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, 574 00 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysa","family":"Sardeli","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoforos","family":"Kosmidis","sequence":"first","affiliation":[{"name":"3rd University General Hospital, \u201cAHEPA\u201d University Hospital, 546 21 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosmas","family":"Tsakiridis","sequence":"first","affiliation":[{"name":"Thoracic Surgery Department, \u201cInterbalkan\u201d European Medical Center, 555 35 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Matthaios","sequence":"first","affiliation":[{"name":"Oncology Department, General Hospital of Rhodos, 851 33 Rhodos, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidong","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Respiratory & Critical Care Medicine, Changhai Hospital, The Second Military Medical University, 200433 Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Respiratory & Critical Care Medicine, Changhai Hospital, The Second Military Medical University, 200433 Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hohenforst-Schmidt","sequence":"first","affiliation":[{"name":"Sana Clinic Group Franken, Department of Cardiology\/Pulmonology\/Intensive Care\/Nephrology, \u201cHof\u2019\u2019 Clinics, University of Erlangen, 91054 Hof, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Pitsiou","sequence":"first","affiliation":[{"name":"Pulmonary Department, \u201cG. Papanikolaou\u201d General Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kioumis","sequence":"first","affiliation":[{"name":"Pulmonary Department, \u201cG. Papanikolaou\u201d General Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Giannakoulas","sequence":"first","affiliation":[{"name":"First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savas","family":"Petanidis","sequence":"first","affiliation":[{"name":"Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysanthi","family":"Karapantzou","sequence":"first","affiliation":[{"name":"Ear, Nose and Throat (ENT) Department, Ludwig-Maximilians University of Munich, 80539 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology. 2003; 56: 588\u2013599.","DOI":"10.1046\/j.1365-2125.2003.01892.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology. 2003; 56: 600\u2013612.","DOI":"10.1046\/j.1365-2125.2003.01893.x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Zarogoulidis P, Papanas N, Kouliatsis G, Spyratos D, Zarogoulidis K, Maltezos E. Inhaled insulin: too soon to be forgotten? Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; 24: 213\u2013223.","DOI":"10.1089\/jamp.2011.0876"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Zarogoulidis P, Petridis D, Ritzoulis C, Li Q, Huang H, Ning Y, et al. Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays\u2019 production systems. International Journal of Pharmaceutics. 2013; 458: 39\u201347.","DOI":"10.1016\/j.ijpharm.2013.10.019"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Langton Hewer SC, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, et al. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT. Health Technology Assessment. 2021; 25: 1\u2013128.","DOI":"10.3310\/hta25650"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yung GL, Kriett JM, Jamieson SW, Johnson FW, Newhart J, Kinninger K, et al. Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: a bridge to lung transplantation. The Journal of Heart and Lung Transplantation. 2001; 20: 1224\u20131227.","DOI":"10.1016\/S1053-2498(01)00304-7"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Badesch DB, Champion HC, Gomez Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and Assessment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 2009; 54: S55\u2013S66.","DOI":"10.1016\/j.jacc.2009.04.011"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of the American College of Cardiology. 2004; 43: 13S\u201324S.","DOI":"10.1016\/j.jacc.2004.02.029"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology. 2009; 54: S43\u2013S54.","DOI":"10.1016\/j.jacc.2009.04.012"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Yaghi S, Novikov A, Trandafirescu T. Clinical update on pulmonary hypertension. Journal of Investigative Medicine. 2020; 68: 821\u2013827.","DOI":"10.1136\/jim-2020-001291"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019; 53: 1801913.","DOI":"10.1183\/13993003.01913-2018"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Richter MJ, Wan J, Ghofrani HA, Seeger W, Gall H, Rieth A, et al. Acute response to rapid iloprost inhalation using the Breelib\u2122 nebulizer in pulmonary arterial hypertension: the Breelib\u2122 acute study. Pulmonary Circulation. 2019; 9: 2045894019875342.","DOI":"10.1177\/2045894019875342"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Fukumoto Y, Shimokawa H. Recent Progress in the Management of Pulmonary Hypertension. Circulation Journal. 2011; 75: 1801\u20131810.","DOI":"10.1253\/circj.CJ-11-0567"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Vane J, Corin RE. Prostacyclin: a Vascular Mediator. European Journal of Vascular and Endovascular Surgery. 2003; 26: 571\u2013578.","DOI":"10.1016\/S1078-5884(03)00385-X"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the TReprostinil sodium Inhalation used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. The Journal of Heart and Lung Transplantation. 2011; 30: 1327\u20131333.","DOI":"10.1016\/j.healun.2011.08.019"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zarogoulidis P, Kioumis I, Lampaki S, Organtzis J, Porpodis K, Spyratos D, et al. Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol. Drug Design, Development and Therapy. 2014; 8: 1065\u20131072.","DOI":"10.2147\/DDDT.S66576"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zarogoulidis P, Kioumis I, Porpodis K, Spyratos D, Tsakiridis K, Huang H, et al. Clinical experimentation with aerosol antibiotics: current and future methods of administration. Drug Design, Development and Therapy. 2013; 7: 1115\u20131134.","DOI":"10.2147\/DDDT.S51303"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Lelong N, Junqua-Moullet A, Diot P, Vecellio L. Comparison of laser diffraction measurements by Mastersizer X and Spraytec to characterize droplet size distribution of medical liquid aerosols. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2014; 27: 94\u2013102.","DOI":"10.1089\/jamp.2012.1030"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zarogoulidis K, Boutsikou E, Zarogoulidis P, Darwiche K, Freitag L, Porpodis K, et al. The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis. OncoTargets and Therapy. 2013; 6: 1493\u20131500.","DOI":"10.2147\/OTT.S52330"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zarogoulidis P, Darwiche K, Krauss L, Huang H, Zachariadis GA, Katsavou A, et al. Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients. Future Oncology. 2013; 9: 1307\u20131313.","DOI":"10.2217\/fon.13.111"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Zarogoulidis P, Darwiche K, Huang H, Spyratos D, Yarmus L, Li Q, et al. Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer. Current Pharmaceutical Biotechnology. 2013; 14: 632\u2013642.","DOI":"10.2174\/13892010113146660229"},{"key":"ref22","unstructured":"Boukovinas I, Tsakiridis K, Zarogoulidis P, Machairiotis N, Katsikogiannis N, Kougioumtzi I, et al. Neo-adjuvant chemotherapy in early stage non-small cell lung cancer. Journal of Thoracic Disease. 2013; 5: S446\u2013S448."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Snyder RJ, Kleeberger SR. Role of Mitochondrial DNA in Inflammatory Airway Diseases. Comprehensive Physiology. 2021; 11: 1485\u20131499.","DOI":"10.1002\/cphy.c200010"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Sala V, Cnudde SJ, Murabito A, Massarotti A, Hirsch E, Ghigo A. Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives. European Journal of Medicinal Chemistry. 2021; 213: 113191.","DOI":"10.1016\/j.ejmech.2021.113191"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Majumder J, Minko T. Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. Advanced Therapeutics. 2020; 4: 2000203.","DOI":"10.1002\/adtp.202000203"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Madney YM, Laz NI, Elberry AA, Rabea H, Abdelrahim MEA. Aerosol delivery aspects within a high-flow therapy system in COPD patients. ERJ Open Research. 2021; 7: 00422\u20132020.","DOI":"10.1183\/23120541.00422-2020"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wright SP, Cheyne WS, Gelinas JC, Harper MI, Sasso JP, Eves ND. Systolic reserve maintains left ventricular-vascular coupling when challenged by adverse breathing mechanics and hypertension in healthy adults. Journal of Applied Physiology. 2021; 130: 1171\u20131182.","DOI":"10.1152\/japplphysiol.00833.2020"},{"key":"ref28","unstructured":"Huang H, Zarogoulidis P, Lampaki S, Organtzis J, Petridis D, Porpodis K, et al. Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil. Journal of Thoracic Disease. 2014; 6: 1411\u20131419."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Pitsiou G, Zarogoulidis P, Petridis D, Kioumis I, Lampaki S, Organtzis J, et al. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Design, Development and Therapy. 2014; 8: 1753\u20131763.","DOI":"10.2147\/DDDT.S70277"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Khan I, Apostolou M, Bnyan R, Houacine C, Elhissi A, Yousaf SS. Paclitaxel-loaded micro or nano transfersome formulation into novel tablets for pulmonary drug delivery via nebulization. International Journal of Pharmaceutics. 2020; 575: 118919.","DOI":"10.1016\/j.ijpharm.2019.118919"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Khan I, Yousaf S, Subramanian S, Korale O, Alhnan MA, Ahmed W, et al. Proliposome powders prepared using a slurry method for the generation of beclometasone dipropionate liposomes. International Journal of Pharmaceutics. 2015; 496: 342\u2013350.","DOI":"10.1016\/j.ijpharm.2015.10.002"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hohenforst-Schmidt W, Hornig J, Friedel N, Zarogoulidis P, Zarogoulidis K, Brachmann J. Successful management of an inadvertent excessive treprostinil overdose. Drug Design, Development and Therapy. 2013; 7: 161\u2013165.","DOI":"10.2147\/DDDT.S42771"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Design, Development and Therapy. 2012; 6: 19\u201328.","DOI":"10.2147\/DDDT.S19281"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and Efficacy of Inhaled Treprostinil as Add-on Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 2006; 48: 1433\u20131437.","DOI":"10.1016\/j.jacc.2006.05.070"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Braet H, Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Van Walleghem T, Cornelis S, et al. Exploring high pressure nebulization of Pluronic F127 hydrogels for intraperitoneal drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2021; 169: 134\u2013143.","DOI":"10.1016\/j.ejpb.2021.10.001"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Reymond M, Demtroeder C, Solass W, Winnekendonk G, Tempfer C. Electrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application. Pleura and Peritoneum. 2016; 1: 109\u2013116.","DOI":"10.1515\/pp-2016-0005"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal. 2004; 25: 2243\u20132278.","DOI":"10.1016\/j.ehj.2004.09.014"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Mogoll\u00f3n MV, Lage E, Cabez\u00f3n S, Hinojosa R, Ballesteros S, Aranda A, et al. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report. Transplantation Proceedings. 2006; 38: 2522\u20132523.","DOI":"10.1016\/j.transproceed.2006.08.074"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Kemp K, Savale L, O\u2019Callaghan DS, Ja\u00efs X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. The Journal of Heart and Lung Transplantation. 2012; 31: 150\u2013158.","DOI":"10.1016\/j.healun.2011.11.002"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Said SI, Hamidi SA. Pharmacogenomics in Pulmonary Arterial Hypertension: toward a Mechanistic, Target\u2010Based Approach to Therapy. Pulmonary Circulation. 2011; 1: 383\u2013388.","DOI":"10.4103\/2045-8932.87306"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/1\/10.31083\/j.fbl2701019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:31:34Z","timestamp":1732707094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/1\/10.31083\/j.fbl2701019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00357-4"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2701019","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"type":"print","value":"2768-6701"},{"type":"electronic","value":"2768-6698"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"article-number":"19"}}